NextCure Inc. and Simcere Zaiming have announced the expansion of the ongoing Phase 1 clinical trial of SIM0505, a novel antibody drug conjugate targeting cadherin-6 (CDH6), into the United States. The first U.S. patient has been dosed at a mid-tier dose level where multiple responses have previously been observed. The multi-regional trial, which began in China, is evaluating safety, tolerability, pharmacokinetics, and efficacy in patients with advanced solid tumors. NextCure expects to present proof-of-concept clinical data in the first half of 2026. No clinical results have been presented yet.